• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    2/9/23 12:31:10 PM ET
    $CSII
    $EIGR
    $EQ
    $EXAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CSII alert in real time by email

    Gainers

    • Cardiovascular Systems (NASDAQ:CSII) shares moved upwards by 48.7% to $19.79 during Thursday's regular session. Cardiovascular Systems's stock is trading at a volume of 8.8 million shares as of 12:30 EST. This is 3383.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $828.8 million. The company's, Q2 earnings came out yesterday.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) shares moved upwards by 39.46% to $2.85. Eiger BioPharmaceuticals's stock is trading at a volume of 4.0 million shares as of 12:30 EST. This is 398.0% of its average full-day volume over the last 100 days. The company's market cap stands at $125.3 million.
    • Surrozen (NASDAQ:SRZN) shares rose 38.94% to $1.07. The current volume of 5.6 million shares is 643.1% of Surrozen's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $31.8 million.
    • Omega Therapeutics (NASDAQ:OMGA) shares moved upwards by 32.22% to $6.36. Omega Therapeutics's stock is trading at a volume of 102.3K shares as of 12:30 EST. This is 194.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $305.5 million.
    • Organovo Holdings (NASDAQ:ONVO) shares increased by 25.25% to $2.43. As of 12:30 EST, this security is trading at a volume of 720.0K shares, making up 2454.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.1 million.
    • Star Equity Hldgs (NASDAQ:STRRP) stock increased by 23.47% to $7.1.

    Losers

    • Tivic Health Systems (NASDAQ:TIVC) stock decreased by 54.0% to $0.23 during Thursday's regular session. Trading volume for Tivic Health Systems's stock is 7.4 million as of 12:30 EST. This is 8509.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 million.
    • Revelation Biosciences (NASDAQ:REVB) shares decreased by 42.36% to $3.09. Trading volume for this security as of 12:30 EST is 1.4 million, which is 4688.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.0 million.
    • Globus Medical (NYSE:GMED) shares fell 18.15% to $62.99. The current volume of 6.8 million shares is 1266.3% of Globus Medical's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $6.2 billion.
    • Equillium (NASDAQ:EQ) stock fell 16.93% to $1.03. As of 12:30 EST, Equillium's stock is trading at a volume of 278.7K, which is 214.3% of its average full-day volume over the last 100 days. The company's market cap stands at $35.4 million.
    • Hillstream BioPharma (NASDAQ:HILS) stock fell 16.9% to $1.14. As of 12:30 EST, this security is trading at a volume of 482.1K shares, making up 30.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.1 million.
    • Exscientia (NASDAQ:EXAI) shares decreased by 15.74% to $9.21. Trading volume for this security as of 12:30 EST is 358.8K, which is 128.5% of its average full-day volume over the last 100 days. The company's market cap stands at $1.1 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CSII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CSII
    $EIGR
    $EQ
    $EXAI

    CompanyDatePrice TargetRatingAnalyst
    Equillium Inc.
    $EQ
    2/25/2026$5.00Buy
    Stifel
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Globus Medical Inc.
    $GMED
    1/30/2026$112.00Hold → Buy
    Needham
    Globus Medical Inc.
    $GMED
    1/27/2026$110.00Buy
    TD Cowen
    Globus Medical Inc.
    $GMED
    11/7/2025$93.00Hold → Buy
    Truist
    Globus Medical Inc.
    $GMED
    11/7/2025$91.00Neutral → Buy
    BofA Securities
    Globus Medical Inc.
    $GMED
    10/28/2025$64.00Hold
    Stifel
    Globus Medical Inc.
    $GMED
    5/27/2025Buy → Neutral
    BTIG Research
    More analyst ratings

    $CSII
    $EIGR
    $EQ
    $EXAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Equillium with a new price target

    Stifel initiated coverage of Equillium with a rating of Buy and set a new price target of $5.00

    2/25/26 7:52:10 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Surrozen with a new price target

    Cantor Fitzgerald initiated coverage of Surrozen with a rating of Overweight and set a new price target of $40.00

    2/19/26 7:52:22 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Globus Medical upgraded by Needham with a new price target

    Needham upgraded Globus Medical from Hold to Buy and set a new price target of $112.00

    1/30/26 6:55:35 AM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $CSII
    $EIGR
    $EQ
    $EXAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, GC, Corporate Secretary Huller Kelly exercised 20,000 shares at a strike of $43.58 and sold $1,890,000 worth of shares (20,000 units at $94.50) (SEC Form 4)

    4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

    2/27/26 5:53:36 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Sr. Vice President and COO Zedelmayer Christine sold $328,104 worth of shares (185,937 units at $1.76) and exercised 185,937 shares at a strike of $0.76 (SEC Form 4)

    4 - Equillium, Inc. (0001746466) (Issuer)

    2/23/26 12:52:51 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Handley Michael K converted options into 8,824 shares (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    2/20/26 4:19:42 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CSII
    $EIGR
    $EQ
    $EXAI
    SEC Filings

    View All

    Tivic Health Systems Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/4/26 8:30:42 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/26/26 4:25:26 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Revelation Biosciences Inc.

    10-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/26/26 4:06:19 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CSII
    $EIGR
    $EQ
    $EXAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $444,844 worth of shares (18,856 units at $23.59) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/13/26 4:19:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Column Group Iii Gp, Lp bought $641,597 worth of shares (32,507 units at $19.74) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/20/26 7:35:33 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CSII
    $EIGR
    $EQ
    $EXAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026 Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com

    2/25/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

    LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a po

    2/25/26 8:30:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Globus Medical Reports Fourth Quarter and Full Year 2025 Results

    AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP net income for the quarter was $140.6 million.GAAP diluted earnings per share ("EPS") was $1.03, an increase of 442.6%. Non-GAAP diluted EPS was $1.28, an increase of 52.1%. Full Year

    2/24/26 4:15:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $CSII
    $EIGR
    $EQ
    $EXAI
    Leadership Updates

    Live Leadership Updates

    View All

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Bu

    8/8/25 4:05:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CSII
    $EIGR
    $EQ
    $EXAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exscientia Plc

    SC 13G/A - Exscientia plc (0001865408) (Subject)

    11/22/24 9:11:55 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Exscientia Plc

    SC 13D/A - Exscientia plc (0001865408) (Subject)

    11/22/24 8:00:16 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CSII
    $EIGR
    $EQ
    $EXAI
    Financials

    Live finance-specific insights

    View All

    Globus Medical Reports Fourth Quarter and Full Year 2025 Results

    AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP net income for the quarter was $140.6 million.GAAP diluted earnings per share ("EPS") was $1.03, an increase of 442.6%. Non-GAAP diluted EPS was $1.28, an increase of 52.1%. Full Year

    2/24/26 4:15:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-

    2/12/26 4:30:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Globus Medical Reports Third Quarter 2025 Results

    AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0 millionGAAP diluted earnings per share ("EPS") was $0.88 and non-GAAP diluted EPS was $1.18, increasing 134.0% and 42.6%, respectively "We are pleased with the strength of our overall results and

    11/6/25 4:15:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care